<a href="https://www.fiercebiotech.com/biotech/fda-refuses-replimunes-melanoma-prospect-second-time" hreflang="en">FDA rejects Replimune’s melanoma prospect for second time</a>
fiercebiotech.com·Apr 10, 2026
The FDA has rejected Replimune's resubmitted application for its melanoma candidate RP1, marking a second setback for the immunotherapy after a previous rejection in July.
For a professional tracking healthtech and biotech developments, the key insight here is the significance of ensuring robust clinical trial data and clear communication with regulatory bodies like the FDA. Replimune's repeated rejection highlights the critical importance of aligning trial design and outcomes with FDA expectations, which is crucial for the success of any biotech venture aiming for FDA approval.